BioSpace News Archive

Intercept Pharmaceuticals, Inc. announced additional supportive data from its pivotal Phase 3 REGENERATE study of obeticholic acid in patients with liver fibrosis due to nonalcoholic steatohepatitis.

Shattuck Labs, Inc. announced preclinical data from the company’s novel GADLEN platform at the 2022 SITC Annual Meeting.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, announced that it has been named the “2022 David J. Gury Company of the Year” by BioFlorida.

Cytovia Therapeutics, Inc. announced new preclinical data for its TALEN® gene-edited, iPSC-derived NK cells and GPC3-targeted Flex-NK™ bispecific antibodies.

Compugen Ltd. announced publication of the abstract on data demonstrating that anti-tumor activity following blockade of PVRIG with COM701 is supported by potent tumor microenvironment immune activation in MSS-CRC patients.

Compugen Ltd. announced publication of an abstract on preliminary data showing anti-tumor activity and potent immune modulation with the combination of COM701 and nivolumab in metastatic MSS-CRC patients.

Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, announced that it will present data on lead therapeutic candidate, PT-112, and its immunological effects on cancer cell mitochondria.

Actym Therapeutics announced today that an abstract highlighting detailed in vivo and in vitro preclinical data of its lead candidate, ACTM-838, was accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022.

A2 Bio today announced four poster presentations will be given on November 10, 2022 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting in Boston, MA.

Incyte (NASDAQ:INCY) and Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced a clinical trial collaboration and supply agreement to investigate the combination of INCB99280, Incyte’s small molecule PD-L1 inhibitor, and adagrasib, a KRASG12C selective inhibitor.